The A2M Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human colorectal adenocarcinoma cell line HT29, engineered to disrupt the A2M gene encoding alpha-2-macroglobulin. This polyclonal population provides a heterogeneous loss-of-function model, avoiding the clonal artifacts that can arise from single-cell-derived lines. The cells serve as a versatile platform for investigating the roles of A2M in protease inhibition, cytokine sequestration, and modulation of the tumor microenvironment.
The HT29 cell line, established from a primary colorectal adenocarcinoma, retains epithelial morphology and is widely employed in cancer biology, drug discovery, and inflammation research. These cells exhibit capacity for enterocytic differentiation and express markers relevant to intestinal physiology. As a model of colorectal cancer, HT29 cells enable the study of oncogenic signaling, therapeutic resistance, and metastatic processes, making them an appropriate host for A2M knockout studies given the gene??s involvement in proteolysis and inflammatory pathways.
A2M functions as a broad-spectrum protease inhibitor through a unique bait-and-trap mechanism, covalently entrapping proteases such as trypsin, thrombin, plasmin, and matrix metalloproteinases like MMP-9. The resulting A2M-protease complexes are recognized by LRP1 and internalized via receptor-mediated endocytosis, facilitating clearance. In addition to protease inhibition, A2M binds and modulates the bioavailability of cytokines and growth factors, including TGF-beta and PDGF. Its expression is regulated by upstream inflammatory mediators such as IL-6, TNF-alpha, and glucocorticoids. Within signaling networks, A2M intersects with the innate immune system, complement and coagulation cascades, and TGF-beta signaling, with downstream effects on NF-kB activation and tissue remodeling. Interacting factors include neutrophil elastase, IL-1beta, and human serum albumin, positioning A2M as a critical node in the balance between proteolytic activity and cytokine-driven signaling.
In the context of HT29 colorectal adenocarcinoma cells, loss of A2M function provides a powerful tool to dissect how protease activity and cytokine availability shape tumor behavior. Colorectal cancer progression is driven by dysregulated extracellular matrix degradation, sustained inflammation, and TGF-beta-mediated signaling; A2M deficiency in these cells may unmask heightened proteolytic capacity and altered responsiveness to growth factors. This knockout model enables the exploration of compensatory mechanisms that emerge when the primary protease inhibitor shield is removed, offering insights into the molecular adaptation of cancer cells within the tumor microenvironment.
Typical research applications for A2M Knockout HT29 Polyclonal Cells include investigation of protease-driven cancer invasion and metastasis, analysis of inflammatory signaling cascades, and evaluation of drug resistance mechanisms. The cells are compatible with a range of assays: western blotting and RT-qPCR for gene expression analysis, protease activity assays, invasion and migration assays, co-immunoprecipitation, ELISA, flow cytometry for LRP1 surface expression, apoptosis assays, and drug sensitivity testing. By enabling precise modulation of the A2M axis, this model supports studies on cytokine modulation and its impact on tumor-stoma interactions. For additional information or technical support, please contact Ascent Research.
